David Joseph

513 total citations
15 papers, 354 citations indexed

About

David Joseph is a scholar working on Radiology, Nuclear Medicine and Imaging, Immunology and Infectious Diseases. According to data from OpenAlex, David Joseph has authored 15 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Radiology, Nuclear Medicine and Imaging, 5 papers in Immunology and 4 papers in Infectious Diseases. Recurrent topics in David Joseph's work include Monoclonal and Polyclonal Antibodies Research (6 papers), T-cell and B-cell Immunology (4 papers) and HIV/AIDS drug development and treatment (4 papers). David Joseph is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (6 papers), T-cell and B-cell Immunology (4 papers) and HIV/AIDS drug development and treatment (4 papers). David Joseph collaborates with scholars based in United States, Germany and New Zealand. David Joseph's co-authors include I. Moore, I. Ishaaya, Susan E. Hattox, Steven J. Padula, Jürgen Steffgen, Steven J. Taylor, James Hilbert, Alison Kukulka, Stéphane De Lombaert and Neil A. Farrow and has published in prestigious journals such as Cancer Research, Journal of Medicinal Chemistry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

David Joseph

14 papers receiving 344 citations

Peers

Countries citing papers authored by David Joseph

Since Specialization

Citations

This map shows the geographic impact of David Joseph's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Joseph with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Joseph more than expected).

Fields of papers citing papers by David Joseph

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Joseph. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Joseph. The network helps show where David Joseph may publish in the future.

Co-authorship network of co-authors of David Joseph

This figure shows the co-authorship network connecting the top 25 collaborators of David Joseph. A scholar is included among the top collaborators of David Joseph based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Joseph. David Joseph is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Improving the Working Models for Drug–Drug Interactions: Impact on Preclinical and Clinical Drug Development 2025 ·Pharmaceutics ·James Nguyen, David Joseph, Xin Chen, (unknown), (unknown), Peter Stopfer, Fenglei Huang	1
2	Comparative therapeutic role of ascorbic acid, α-tocopherol and riboflavin in mitigating hepatotoxicity induced by drugs and chemical toxins – a review 2025 ·European Journal of Clinical and Experimental Medicine ·(unknown), David Joseph	0
3	Abstract LB270: Absorption, distribution, metabolism and excretion (ADME) properties and absolute bioavailability of zongertinib, a selective oral HER2-specific tyrosine kinase inhibitor, in healthy male subjects 2025 ·Cancer Research ·David Joseph, Rolf Grempler, (unknown), (unknown), (unknown), (unknown), (unknown), Sven Wind, (unknown)	1
4	Assessment of the Pharmacokinetics and Safety of Spesolimab, a Humanised Anti-interleukin-36 Receptor Monoclonal Antibody, in Healthy Non-Japanese and Japanese Subjects: Results from Phase I Clinical Studies 2022 ·Clinical Pharmacokinetics ·David Joseph, Christian Thoma, Thomas Haeufel, Xiujiang Li	8
5	Effects of BI 655064, an antagonistic anti-CD40 antibody, on clinical and biomarker variables in patients with active rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase IIa study 2019 ·Annals of the Rheumatic Diseases ·Sudha Visvanathan, (unknown), (unknown), Ulf Müller‐Ladner, Meera Ramanujam, (unknown), Anastasia G Eleftheraki, Richard Vinisko, (unknown), Herbert Kellner, Eva Dokoupilová, Brygida Kwiatkowska, Rieke Alten, Christian Schwabe, Patrick Baum, David Joseph, Jay S. Fine, Steven J. Padula, Jürgen Steffgen	44
6	Retrospective analysis of model-based predictivity of human pharmacokinetics for anti-IL-36R monoclonal antibody MAB92 using a rat anti-mouse IL-36R monoclonal antibody and RNA expression data (FANTOM5) 2019 ·mAbs ·Jennifer Ahlberg, Craig Giragossian, Hua Li, (unknown), (unknown), Gary Caviness, Christine Grimaldi, Su-Ellen Brown, (unknown), Danlin Yang, Rachel Kroe‐Barrett, David Joseph, Chandrasena Pamulapati, (unknown), Peter Ruus, Joseph R. Woska, Rajkumar Ganesan, Steven Hansel, M. Lamine Mbow	8
7	Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases 2018 ·The Journal of Clinical Pharmacology ·Christian Schwabe, (unknown), (unknown), Paul Hamilton, P. Rod Dunbar, Anastasia G Eleftheraki, David Joseph, James Hilbert, Corinna Schoelch, Steven J. Padula, Jürgen Steffgen	21
8	Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases 2017 ·European Journal of Clinical Pharmacology ·(unknown), Frank Wagner, Andreas Hüser, (unknown), David Joseph, James Hilbert, Corinna Schoelch, Steven J. Padula, Jürgen Steffgen	30
9	Effect of Steady-State Faldaprevir on the Pharmacokinetics of Steady-State Methadone and Buprenorphine-Naloxone in Subjects Receiving Stable Addiction Management Therapy 2014 ·Antimicrobial Agents and Chemotherapy ·David Joseph, (unknown), (unknown), Bradley Vince, Lynn R. Webster, Abidemi Adeniji, Mabrouk Elgadi, Fenglei Huang	4
10	Effect of faldaprevir on raltegravir pharmacokinetics in healthy volunteers 2014 ·The Journal of Clinical Pharmacology ·David Joseph, Peter W. Rose, Natalja Strelkowa, Armin Schultz, Jeanette M. Garcia, Mabrouk Elgadi, Fenglei Huang	5
11	Structure-Based Optimization of Arylamides as Inhibitors of Soluble Epoxide Hydrolase 2009 ·Journal of Medicinal Chemistry ·Anne B. Eldrup, (unknown), Steven J. Taylor, Ingo Muegge, Neil A. Farrow, David Joseph, (unknown), (unknown), Alison Kukulka, Stéphane De Lombaert	52
12	Biotransformation of Nevirapine, a Non-nucleoside HIV-1 Reverse Transcriptase Inhibitor, in Mice, Rats, Rabbits, Dogs, Monkeys, and Chimpanzees 1999 ·Drug Metabolism and Disposition ·(unknown), David Joseph, (unknown), Walter Davidson, James J. Keirns, Susan E. Hattox	32
13	Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 8. 8-Aryloxymethyl- and 8-Arylthiomethyldipyridodiazepinones 1998 ·Journal of Medicinal Chemistry ·Charles L. Cywin, Janice M. Klunder, (unknown), (unknown), Eva David, Peter M. Grob, (unknown), Daniel Pauletti, Kevin Barringer, Cheng-Kon Shih, Christopher L. Sorge, David A. Erickson, David Joseph, Susan E. Hattox	24
14	Novel Nonnucleoside Inhibitors of HIV-1 Reverse Transcriptase. 7. 8-Arylethyldipyridodiazepinones as Potent Broad-Spectrum Inhibitors of Wild-Type and Mutant Enzymes 1998 ·Journal of Medicinal Chemistry ·Janice M. Klunder, (unknown), Charles L. Cywin, Eva David, (unknown), (unknown), Kevin Barringer, Daniel Pauletti, Cheng-Kon Shih, David A. Erickson, Christopher L. Sorge, David Joseph, Susan E. Hattox, Julian Adams, Peter M. Grob	27
15	Protease and amylase activity in larvae of the Egyptian cotton worm, Spodoptera littoralis 1971 ·Journal of Insect Physiology ·I. Ishaaya, I. Moore, David Joseph	97

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact